This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary IL-13 Therapeutic Antibody Development
Background of IL-13
IL-13 is considered a potential therapeutic target in allergic diseases for treatment in companion animals, such as atopic dermatitis, promising more effective treatment options for a range of conditions. BioVenic offers veterinary IL-13 therapeutic antibody development services, covering the entire process from gene synthesis and animal immunization to antibody preparation and purification, providing a one-stop service to advance the field of animal health.
Background of IL-13
| Full Name | Interleukin 13 |
|---|---|
| Aliases | ALRH, BHR1, IL13, P600. |
| Target Profile | IL-13 is a member of the immunoregulatory cytokine family, predominantly produced by Th2, and plays a crucial role in modulating immune responses and inflammatory processes. In respiratory inflammation and allergic diseases, IL-13 promotes the proliferation of airway smooth muscle cells and fibroblasts and increases mucus secretion, leading to airway inflammation and hyperresponsiveness. IL-13's biological functions are closely linked to IL-4, with which it often acts synergistically in many biological processes. |
MoA of IL-13
IL-13 signals through its binding to the type II IL-4 receptor (IL-4R α and IL-13R α1). It also binds to IL-13R α2, a chain that lacks a transmembrane signaling domain and is considered to act as a decoy receptor. The activation of IL-13R α1 triggers TYK2 and JAK2, subsequently phosphorylating STAT-6, which dimerizes, migrates to the nucleus, and binds to the promoters of IL-4 and IL-13 responsive genes. These genes are associated with type II Th2 cell differentiation, airway inflammation, airway hyperresponsiveness, and mucus production.
Fig.1 Schematic diagram of IL-13 signaling pathways.1
Application in Veterinary Therapeutics
Allergies, including atopic dermatitis and asthma, are common in companion animals like canine, feline, and equine. Elevated levels of IL-13 in the plasma of canines with atopic dermatitis support the hypothesis that IL-13 plays a crucial role as a mediator in allergic inflammation. Therapeutic strategies targeting IL-13, such as the use of IL-13 antibodies, can reduce the signaling of IL-13 in these species, assisting in alleviating the dysfunctions caused by the overexpression of IL-13, such as impaired skin barrier function as well as excessive airway inflammation and mucus secretion, improving the health condition of these animals.
Veterinary IL-13 Therapeutic Antibody Development Services
IL-13 is a pivotal cytokine in inducing and sustaining type II inflammatory responses, linked to various allergic diseases in companion animals. BioVenic has established a specialized platform for developing veterinary IL-13 therapeutic antibodies. Leveraging our extensive expertise in antibody development, our team employs advanced technologies like hybridoma, single B cell, and phage display to ensure the high quality of the developed IL-13 antibodies. Additionally, we offer comprehensive antibody characterization and engineering services, aiming to produce antibodies with high affinity and reduced immunogenicity.
Please click the link below for more information about our veterinary IL-13 therapeutic antibody development services.
Why Choose Us?
BioVenic provides comprehensive veterinary therapeutic antibody development services covering the entire key stages, from initiating immune responses in animals to antibody preparation, selection, and final validation.
Our antibody engineering services include antibody caninization/felinization, affinity maturation, and Fc engineering to extend the antibodies' half-life in specific species while reducing potential immunogenicity.
To ensure the efficient and safe use of antibodies, we offer species-specific antibody development services to reduce the risk of immunogenicity and improve therapeutic safety.
Given the pivotal role of IL-13 in common allergic diseases such as dermatitis and respiratory disorders in companion animals, understanding this target opens up potential treatment avenues for a range of conditions. BioVenic offers professional veterinary IL-13 therapeutic antibody development services, ensuring to meet your needs at every stage of development. If you are considering developing veterinary IL-13 therapeutic antibodies, please do not hesitate to contact us for more information.
References
- Tubau, Carla, and Lluís Puig. "IL-13 antagonists in the treatment of atopic dermatitis." Immunotherapy 13.4 (2021): 327-344.
- Majewska, Alicja, et al. "Lymphocytic, cytokine and transcriptomic profiles in peripheral blood of dogs with atopic dermatitis." BMC veterinary research 12.1 (2016): 1-14.